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This review summarizes the major long-term (10 to 15 years) patient outcomes after
insertion of many Food and Drug Administration approved prosthetic heart valves (PHV).
Mechanical PHV was associated with a better survival (p 0.02) at 15 years after aortic valve
replacement (AVR) than with a bioprosthesis in the Department of Veterans Affairs (DVA)
trial. In both the DVA and the Edinburgh Heart Valve trials, bioprosthesis were associated
with structural valve deterioration (SVD) (mitral valve replacement [MVR]  AVR) and,
therefore, for replacement of the PHV. Thromboembolism and bleeding rate were higher
with mechanical PHV. Mortality after AVR and MVR is high at 10 to 15 years because of
the associated comorbid conditions and older age of patients. Outcomes with “new” good
valves are similar to that with “older” good valves. Complication rates of thromboembolism,
bleeding, endocarditis, and leak vary widely; the rates of these complications are not different
among different mechanical PHV and among different bioprosthetic PHV. Structural valve
deterioration is rare with mechanical PHV. Structural valve deterioration of bioprosthesis
after MVR is higher than after AVR; after AVR, homografts and bioprosthesis have similar
rates of SVD. The exact rate of SVD of the pulmonary autograft is uncertain. Valve
prosthesis-patient mismatch is clinically important when it is severe and in selected patients
when it is moderate. Bioprosthesis have a low rate of SVD in the older patient and, thus, are
the PHV of choice for AVR in patients60 to 65 years of age and for MVR in patients65
to 70 years of age; in younger patients mechanical valves are the PHV of choice. In individual
patients there may be exceptions to these general rules. (J Am Coll Cardiol 2003;41:
893–904) © 2003 by the American College of Cardiology Foundation
“You believe that easily, which you hope for earnestly.”
Terence (1) c. 190 to 159 B.C.
“What ardently we wish, we soon believe.”
Young (2) 1683 to 1765
HAS MUCH CHANGED SINCE THEN?
The results of valve surgery with regard to survival, compli-
cations, valve function, cardiac function, and functional class
are dependent on patient-related factors, type of surgery,
type of prosthesis, and health care-related factors (3). In
1974, McGoon (4) pleaded for a more systematized process
of evaluation of patients after valve replacement. In 1975, it
was suggested that one way to evaluate differences in patient
outcomes between different valves was by a prospective
randomized trial (5), which led to the planning and perfor-
mance of the Department of Veterans Affairs (DVA)
randomized trial between a mechanical and bioprosthetic
valve (6). Bioprosthesis applies to nonviable tissue of bio-
logical origin such as porcine or bovine pericardium (heter-
ograft or xenograft valves) (7). This report summarizes the
major long-term (10 to 15 years) patient outcomes of many
Food and Drug Administration (FDA)-approved prosthetic
heart valves (PHV) in the last 27 years in order to develop
suggestions for choice of a PHV in individual patients.
RANDOMIZED TRIALS
Two large randomized trials have compared patient out-
comes with use of a mechanical valve (spherical tilting disk
Bjork-Shiley) and a porcine valve (Hancock or Carpentier-
Edwards).
Edinburgh heart valve trial. A total of 541 men and
women were randomized between 1975 to 1979; 211 had
aortic valve replacement (AVR), 261 had mitral valve
replacement (MVR), and 61 had AVR plus MVR (8) (Fig.
1). The average follow-up was 12 years. The major findings
were: 1) there was a trend toward an improved survival with
the Bjork-Shiley valve (p  0.08); 2) reoperation rates were
low and nonsignificant at 5 years; at 12 years there was a
higher reoperation rate with the porcine valve versus me-
chanical valve (AVR, 22.6 5.7% vs. 4.2 2.1%, p 0.01;
MVR, 43.1  6.0% vs. 9.9  3.2%, p  0.001); younger
patients were more likely to require reoperation, with
“relative risk of reoperation increasing 55% for each 10
years, continuously over the whole range of ages studied”; 3)
the incidence of thromboembolism and of endocarditis were
not statistically significantly different; and 4) the bleeding
rate was higher with the mechanical valve versus porcine
valve after AVR (32.6  6.1% vs. 9.7  4.7%, p  0.001)
but not after MVR (24.5% vs. 24.5%).
DVA trial. A total of 575 men were randomized between
1997 to 1982; 394 had AVR, and 181 had MVR (6).
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Follow-up was up to 18 years; average follow-up was 15
years. The principal long-term findings were: 1) after AVR,
use of mechanical valve resulted in a lower mortality (66 
3% vs. 79  3%; p  0.02) (Fig. 1) and a lower reoperation
rate (10  3% vs. 29  5%, p  0.004). The difference
became apparent after 10 years, indicating the need for
follow-up of 15 years. The mortality after MVR was
similar (81% vs. 79%); 3) after AVR, about 40% of the
mortality was related to the PHV; after MVR, 44% of the
mortality with mechanical valve and 57% of the mortality
with bioprosthesis were related to the PHV; 4) there was no
structural valve deterioration (SVD) with the mechanical
valve; 5) primary valve failure occurred mainly in patients
65 years; it began at 5 to 6 years after MVR and at 7 to 8
years after AVR; its incidence was higher after MVR (44 
8% vs. 23  5%); 6) more than 10 years of follow-up was
needed to determine the incidence and deleterious effects of
SVD with use of porcine valve; 7) the primary valve failure
rate between bioprosthesis and mechanical valve was not
significantly different in those 65 years after AVR; 8) use
of a bioprosthetic valve resulted in a lower bleeding rate; and
9) there were no significant differences between the two
valve types with regard to other valve-related complications,
including thromboembolism and all complications.
Major differences between the two trials. The bleeding
rate in the Edinburgh Heart Valve trial was 2% to 2.5%/year
with the mechanical valve and 0.9% to 2%/year with the
porcine valve (3,8). The patients were less heavily antico-
agulated and minor bleeding was not recorded for the first
five years of follow-up. After MVR, the bleeding rates with
a mechanical and porcine valve were not different, probably
because many patients with porcine valves needed antico-
agulation for other reasons, most likely atrial fibrillation.
The exact reasons for the high bleeding rate in the DVA
trial are not clear (6). In the DVA trial, it was recommended
that prothrombin time should be maintained at 2.0 to 2.5
control (3), which is excessive anticoagulation. Also, some
patients with porcine valves were anticoagulated, and all
bleeding episodes were included because it is not possible to
separate bleeding due to anticoagulation from that due to
other causes.
NUMBER OF PATIENTS. The DVA trial had 87% more
patients undergoing isolated AVR and 31% fewer patients
undergoing isolated MVR than the Edinburgh Heart Valve
trial. These differences may account for differences in
outcomes, especially with regard to mortality.
NONRANDOMIZED STUDIES
Mortality. The 10- and 15-year mortality rates after AVR
(Table 1) and MVR are high (9–21). The range is large,
even with the use of the same brand of PHV, indicating the
importance of factors other than the type of PHV. Risk
factors for late mortality have included decade of age, left
ventricular dysfunction, heart failure, New York Heart
Association (NYHA) functional classes III and IV, coronary
Abbreviations and Acronyms
AVR  aortic valve replacement
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
DVA  Department of Veterans Affairs
FDA  Food and Drug Administration
INR  international normalized ratio
NYHA  New York Heart Association
LVEF  left ventricular ejection fraction
MO  modified orifice
MVR  mitral valve replacement
OPC  optimal performance characteristics
PHV  prosthetic heart valve
SVD  structural valve deterioration
VP-PM  valve prosthesis-patient mismatch
Figure 1. Mortality after aortic valve replacement (AVR) with the Bjork-Shiley and porcine valves from the Department of Veterans Affairs trial. From
reference 6.
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artery disease (CAD), coronary artery bypass grafting
(CABG), valve regurgitation, arrhythmias, male gender,
pulmonary hypertension, and comorbid conditions such as
renal failure, lung disease, hypertension, and diabetes
(12,13,16). For example, of 843 patients undergoing AVR
with the Hancock modified orifice (MO) porcine valve (16),
the 10-year late mortality (i.e., excluding 5% operative
mortality) was 48  2%; however, the 10-year mortality in
those with associated CABG was 55  6% versus 39  3%
(p  0.0005) in those without CABG.
The older the patient at the time of PHV implantation,
the lower the 10- to 20-year survival (Fig. 2) (22). Older
patients are more likely to have clinically significant associ-
ated comorbid conditions that are known to adversely affect
survival after PHV (see the preceding text). This study
provided virtually no information on the patients condition
at baseline; thus, it is not possible to know whether the
lower long-term survival (22) was the result of older age
and/or associated cardiac and noncardiac comorbid condi-
tions. It may be trite, but obviously needs repeating that, the
Table 1. Long-Term Mortality After AVR
Author (Ref. No.) Type of PHV
No. of
Patients
Mortality
at Yr %
Orszulak et al. (9) Starr-Edwards 1,100 10 40.4
15 55.1
20 68.8
Lindblom et al. (10) Bjork-Shiley 1,753 10 30*
15 46*
Lund et al. (11) St. Jude 694 10 42  5
Butchart et al. (12) Medtronic Hall 736 10 36
15 55
Peterseim et al. (13) St. Jude 412 10 50  6
C-E porcine 429 10 46  3
Yun et al. (14) Hancock porcine 652 12 49  2
Hancock MO porcine 561 12 58  3
C-E porcine 389 12 56  7
Jamieson et al. (15) C-E supra-annular 1,335 10 40.6  2.1
porcine 12 45.8  2.8
Cohn et al. (16) Hancock MO porcine 843 10 48  2*
15 72  3*
Khan et al. (17) Hancock porcine/ 243 10 45*
Hancock MO porcine 15 64*
Frater et al. (18) C-E pericardial 267 14 60.7  3.1*
David et al. (19) Hancock II porcine 670 10 39  2
15 53  3
*Excluding operative mortality.
AVR  aortic valve replacement; C-E  Carpentier-Edwards; MO  modified orifice; PHV  prosthetic heart valve.
Figure 2. Survival up to 30 years after prosthetic heart valve (PHV) replacement by the patient’s age at time of PHV implantation. From reference 22. For
limitations of this study, see text.
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older one gets, the closer one is to death (an old Asian
saying).
Of note, a study of 841 patients undergoing AVR (13)
showed that subgroups with lower survival at 10 years were
those with renal disease at any age (survival, 27  8%), lung
disease in patients older than 60 years (survival, 30  6%),
left ventricular ejection fraction (LVEF) 0.40 (35  6%),
CAD any age (survival, 35  5%), and age 65 years
(survival, 41  4%).
These data indicate that patient characteristics at baseline
are a major determinant of late mortality after PHV
replacement.
“Older” valves versus “newer” valves. In the 1960s and
1970s, patients with severe aortic stenosis in NYHA func-
tional classes III and IV and clinical heart failure had AVR
with use of the #1260 Starr-Edwards valve (23). After
AVR, LVEF increased from 0.34  0.03% to 0.63 
0.05%, heart failure was relieved, 91% of the patients were
in NYHA functional classes I and II; the 7-year survival was
67  11% and, in operative survivors, was 84  10%. This
is better than the known90% mortality at one to two years
in medically treated patients with severe aortic stenosis and
heart failure (24).
Data from the Mayo Clinic (9) showed that, with use of
the Starr-Edwards model #1260 valve, the 10- and 20-year
survival after AVR was 60% and 35% (Table 1); the
incidence of thromboembolism was 1.4% per year. Albert
Starr’s data of event rates with Starr-Edwards valves #1260
and #6120 up to 30 years after AVR and MVR are good
(25). Preliminary data (five years) from a prospective ran-
domized trial from London, UK, showed no statistically
significant difference in patient outcomes between the St.
Jude and Starr-Edwards valves (26). Mortality and compli-
cation rates in patients with use of various PHVs with
follow-up longer than 10 years are described in detail (vide
supra and infra) and indicate there were no major differences
in patient outcomes with use of the various PHVs among
mechanical PHV and among bioprosthesis. In the DVA
trial, there was not a single instance of SVD with the “old”
Bjork-Shiley valve to 18 years of follow-up (6). In summary,
there is no good evidence that, in patients with similar or
“identical” characteristics at baseline, patient outcomes are
better with “newer good” PHVs than with “older good”
PHVs.
Complications of PHVs. To approve a PHV, the FDA
(27,28) requires studies with 800 valve years of follow-up.
The incidence of complications should be 2 optimal
performance characteristics (OPC) determined by the
FDA, which were calculated to allow an alpha error of 5%
(p  0.05) and beta error of 20% (power of 80%).
A review (29) of mechanical valves comprising 95 pub-
lished series, 37,253 valves, and 187,220 valve-years of
follow-up and of biological valves (porcine, pericardial, and
homograft) comprising 70 published series, 24,202 valves,
and 132,519 valve years of follow-up shows: 1) there is no
significant difference among the various mechanical valves
for thromboembolism (Fig. 3), and also among the various
bioprosthesis; this is also true for rates of thrombosis,
bleeding, endocarditis, and leak; they are also within the 2
 OPCs; 2) the incidence of thromboembolism is higher in
patients with mitral PHV than in those with aortic PHV; 3)
bioprosthesis are not free of thromboembolic risk, but the
risk is lower than with use of a mechanical valve; 4)
complication rates with use of the same brand of PHV
varies widely; and 5) the risk of SVD with all currently used
mechanical valves is “negligible” (29) (i.e., very small).
These findings reconfirm that, with the use of FDA-
approved PHV, these complications are largely related to
factors other than the type of PHV.
Patients undergoing PHV implantation with a mechan-
ical valve who are at the lowest risk of thromboembolism are
those in sinus rhythm; have normal left ventricular function;
have not had previous thromboembolism; do not smoke; do
not have thrombus in left ventricle and/or left atrium,
coronary or carotid disease, diabetes or hypertension; are
seronegative for Chlamydia pneumoniae; have adequate and
low anticoagulation variability; and do not have clotting
disorder(s) (3,30–32).
Bleeding. The bleeding rates associated with use of a
variety of mechanical aortic valves and with a variety of
mechanical mitral valves are similar (29). The data on
bleeding in the two trials are discussed in the preceding text.
In the randomized trials of anticoagulation in atrial fibril-
lation, patients average age ranged from 67 to 75 years, the
incidence of major bleeding in the placebo group ranged
from 0% to 4.6% per year, and the incidence of minor
bleeding was up to 10.5% per year, and there were some
deaths from bleeding (33–38). The bleeding rates were
obtained with follow-up times of about two years; thus,
bleeding rates might be higher if obtained over longer
Figure 3. Thromboembolism rates for mechanical aortic valves. The
vertical axis is the linearized rate in percentage per year. Each symbol
represents one series. Circles indicate that only late events were used to
calculate the rates; diamonds indicate that both early and late events were
used. BS  Bjork Shiley; CM  Carbomedics; ET  Edwards Tekua or
Duromedics; MH  Medtronic Hall; MS  Monostrut; OC  Omni-
carbon; OPC  FDA’s Objective Performance Criteria (from reference
29); OS  Omniscience; SB  Sorbin Bicarbon; SE  Starr Edwards; SJ
 St. Jude; UC  Ultracor. From reference 29.
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follow-up times. Indeed, in patients with mechanical valves
and the same level of anticoagulation, at 7 years, patients
60 years of age had up to seven times the bleeding rate
than that of patients 60 years of age (39). In the Stroke
Prevention in Atrial Fibrillation III (40) trial with interna-
tional normalized ratio (INR) of 2.0 to 3.0, the incidence of
bleeding was 1.5%/year, which is what one would expect
with AVR in sinus rhythm according to current practice.
With MVR, it will be somewhat higher because the INR
after MVR is maintained at a higher level (6).
SVD. The rate of SVD of bioprostheses is importantly
related to: 1) the site of PHV implantation (SVD in MVR
 in AVR); (6,8,29), and 2) to the age of the patient at time
of PHV implantation (29). In patients age 16 to 39 years, at
10 years, SVD after AVR is 60% and at 16 years is 90%,
whereas in patients 70 years, it is 15% at 15 years (14).
The rate of SVD at 12 years in patients followed for more
than 10 years is high with aortic and mitral porcine valves
and with aortic homografts (Fig. 4) (29). It is lowest with
Carpentier-Edwards pericardial valve for AVR (Fig. 4),
which may partly be accounted for by the older age of the
patient at the time of PHV implantation (29). In in vitro
studies, the pericardial aortic valve has lower gradient and
larger PHV area when compared with several other PHV
(41) and also a larger estimated aortic PHV area in patients
in valve sizes 19 to 29 (42) (Fig. 5). These data indicate that
the pericardial aortic valve may be the bioprosthesis of
choice in “older” people (60 to 65 years of age). Patients
65 to 70 years also have a lower rate of SVD after MVR
(30). The rate of SVD is not significantly different for the
standard Hancock, Hancock MO, and Carpentier-Edwards
porcine valves (43). The rate of SVD of newer porcine
valves (Hancock MO and the stentless porcine valve)
(16,44) at nine years is within the expected range of SVD of
earlier stented porcine valves (43) (Fig. 6), indicating that, at
present, all porcine valves have similar rates of SVD.
PHV size. Is it clinically important? Yes and no. The
original 1978 report on valve prosthesis-patient mismatch
(VP-PM) (45) stated that VP-PM “can be considered to be
present when the effective prosthetic valve area, after inser-
tion into the patient, is less than that of a normal human
valve. The reduced prosthetic valve area is usually mild to
moderate in severity and often of no immediate clinical
significance. However, occasionally it can be a severe prob-
lem because the patient may be hemodynamically and
symptomatically worse after valve replacement,” which was
subsequently documented (45–47).
Pibarot and Dumesnil’s (48) extensive review of VP-PM
showed that, depending on its severity, VP-PM may result
in higher valve gradients at rest and on exercise, less
reduction of left ventricular mass, greater physical limita-
tion, and higher morbidity and mortality.
The present review emphasizes a few features of VP-PM:
1) in patients with severe aortic stenosis, mean aortic valve
gradient 30 mm Hg, heart failure, and LVEF 0.35; the
only predictor of an operative mortality of 21% was a small
prosthesis size (47% for PHV 21 mm vs. 15% for PHV
23 mm, p  0.03) (49). In another study, only small body
size was identified in the early hazard phase for mortality
(50). Thus, an appropriate-sized prosthesis may be more
important in the early hazard phase in critically ill patients.
A clue to appropriate size may be determined preoperatively
(48); 2) He´ et al. (51) have shown that, in patients with
small aortic root who received PHV sizes21 mm, the only
independent predictor of poorer 10-year survival was patient
size. In patients with body surface area 1.7 m2 vs. those
1.7 m2, the survival was approximately 10% versus 50% (p
 0.014). Thus, VP-PM is dependent not only on the small
annulus/root but also on the size of the patient. For
example, 19-mm valves produced only mild VP-PM in two
studies from Asia (52,53), but, in the study from North
America, almost half of the patients had moderate or severe
VP-PM, the improvement in NYHA functional class was
less, and, at five years, the incidence of clinical heart failure
was significantly greater (15  3% vs. 7  2%, p  0.05)
(54). People in some countries are smaller than in others,
and in each country women are, on an average, smaller than
men. In the study from Pisa, Italy (55), 28% of patients with
the 19-mm St. Jude valve had severe VP-PM versus 5% of
those with the 21-mm valve (p  0.004). Thus, 82% of
patients who received 19-mm PHV did not have severe
VP-PM; 89% of patients who received the 19-mm valve
Figure 4. Freedom from structural valve degeneration with four types of
biological valves with the superimposed Weibull distribution fits. Modified
and adapted from reference 29.
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were women, indicating that smaller patients who receive a
small PHV may not have severe VP-PM; 3) associated
CABG was an independent predictor of mortality in the He
et al. (51) study; the 10-year survival of those who had
associated CABG versus those who did not was approxi-
mately 35% versus 60%, p  0.0002 (51). In the Connolly
et al. study (49), the 3- and 5-year survival of those with
CAD was 58% and 28% (49), and, in those without CAD,
was 71% and 71% (49); 4) on the other hand, another study
(50) stated that, after AVR patients who received 19 mm,
PHV had a similar long-term survival as those who had
received larger PHV and concluded that moderate VP-PM
appears not to adversely affect survival. This suggestion is
not new (45). The study is problematic because: 1) patients
undergoing simultaneous CABG were excluded; 2) smaller
patients had received a smaller size PHV; thus, PHV area
corrected for body size needs to be calculated. The PHV
area was calculated on the manufacturer’s stated in vitro size
of the inserted PHV and not on the PHV area weeks and
months after insertion into the patient. The manufacturers
stated in vitro valve size does not necessarily mean all valves
of any one size, even of the same brand, have exactly the
Figure 5. Estimated effective orifice area (prosthetic heart valve [PHV] area) of four different bioprosthesis based on manufacturer’s specifications for each
valve size. Figure constructed from data in Table 1 in reference 42. Carpentier-Edwards (C-E) pericardial valve (line) has the largest PHV area in valve
sizes 19 to 29 mm. Although the actual PHV areas after PHV insertion will be lower, starting with a larger valve area is an advantage that could be
important. SAV  supra-annular valve.
Figure 6. Failure-free rate of the Hancock modified orifice (MO) valve (from reference 16) and the stentless valve (from reference 44). “Porcine limits” are
the limits of failure of stented bioprosthesis failure rates (from reference 43).
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same PHV area (48). Moreover, after PHV insertion, tissue
in-growth and endothelialization occur the extent of which
varies from patient to patient. Both of these factors result in
a range of PHV areas for any given valve size (56).
Furthermore, multiple, complex statistical analyses were
used to determine PHV areas (50); 3) data were not
provided on the causes of late deaths. It is possible that most
patients with PHV  19 mm might have died of causes
related to PHV, whereas, in those with larger PHV, most
patients might have died of causes not related to the PHV.
Note that, in the DVA trial, after AVR, only 40% of late
deaths were prosthesis-related; and 4) there was no infor-
mation about the patients functional class, symptomatic
status, cardiac function, and complications, such as heart
failure; 5) the study of Milano et al. from Pisa, Italy (55),
showed that, at 15 years, patients who received a 19-mm St.
Jude valve when compared with those who received the
21-mm St. Jude valve had a poorer NYHA functional class;
less left ventricular mass reduction; and had a higher
incidence of severe VP-PM (18% vs. 5%, p  0.004);
congestive heart failure (7.5  0.8 vs. 0.5  0.2%, p 
0.002); valve-related death, including sudden death (16 
6% vs. 10  5%, p  0.02); and cardiac events (43  13%
vs. 14 4%, p 0.008). Valve prosthesis-patient mismatch
was calculated on basis of PHV area obtained by echocar-
diography/Doppler at time of hospital discharge after PHV
implantation, and those with severe VP-PM had higher
cardiac event rates (Fig. 7).
For long-term outcomes, the issue is not PHV size before
valve replacement but the effective prosthetic valve area
month(s) (? 6 months [56]; ? 12 months [48]) after insertion
into the patient and on the patient’s body size. The outcome
of the patient depends on patient-related and other factors
and also on whether PHV produces mild, moderate, or
severe VP-PM (Table 2).
Homografts (allografts). Homografts for AVR have a
similar rate of SVD as bioprosthesis (Fig. 4) (29). O’Brien
et al. (57–59) reported: 1) in 1987, a 0% incidence of SVD
Figure 7. Percentage actuarial freedom from cardiac events up to 15 years of the St. Jude 19- to 21-mm valves by the prosthetic heart valve (PHV) effective
orifice area index (EOAi) (calculated from the echocardiographic/Doppler valve area obtained at time of hospital discharge after PHV insertion). Adapted
from reference 55.
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at 10 and 15 years in 192 viable cryopreserved valves; 2) in
1991, the “assumed” SVD of 410 cryopreserved valves at 15
years was 15%; 3) in 2001, at 15 years, the reoperation rate
for SVD off cryopreserved valves in those age 0 to 20 years
at time of PHV implantation was 53%, in those age 21 to
40 was 15%, in those age 41 to 60 years was 19%, and in
those age 60 years was 16%. In this study “preservation
techniques (4°C or cryopreservation) and implantation tech-
niques displayed no difference in the overall actuarial
20-year incidence of late survival, endocarditis, thromboem-
bolism, or structural degeneration requiring reoperation,”
and 4) in 2002, of 570 patients (age: 48  16 years) with
cryopreserved homografts undergoing echocardiographic/
Doppler study at 6.8  4.1 years after AVR, 72.1% patients
had signs of homograft dysfunction (i.e., SVD) on echocar-
diography (60). By American College of Cardiology/
American Heart Association guidelines criteria for aortic
stenosis, severe stenosis was present in 2.5% and moderate
stenosis in 10%; moderate to severe regurgitation was
present in 15.4%. It needs to be emphasized that reopera-
tion rates for SVD may not account for all SVD.
The pulmonary autograft for AVR (Ross principle) (61).
The Ross principle is a more complex and more difficult
procedure, but has at least some very major advantages,
namely, when inserted in children, the valve “grows” (in-
creases in size) as the child grows, and pregnancy may not
result in SVD (61,62). The incidence of thromboemboli was
0% to 1.2% per year; of infective endocarditis, was 0% to
1.2% per year; the rate of reoperation within the first six
months was 0%, 1.5%, and 3.8% in three different studies,
and in one small study was 10%, and late reoperation rates
ranged from 0.4% to 1.5% per year (29). Those with
rheumatic heart valve disease (63,64) may develop rheu-
matic valvulitis in the autograft.
The only studies with follow-up greater than 10 years are
four from Ross’s group (65–68). In these four studies: 1) the
respective operative mortality was 6.6%, 7.4%, 7.4%, and
13%, respectively; 2) the survival was 57.3  9.6% at 19
years (65), 80% and 80% at 20 years (66,67), and, after
excluding operative mortality, was 61% at 20 years (68); and
3) the freedom from autograft replacement was 48.5% 
13.7% at 19 years (65), 85% and 85% at 20 years (66,67),
and 75% at 20 years (68). The range of freedom from
autograft replacement is most likely because of selection of
patients reported in these four studies.
The International Registry of the Ross Procedure (69)
has data on 2,523 patients from the world. There are very
major concerns about the information in this database: 1)
data entry is voluntary; the Registry has no information
whether all patients from any one center are reported to the
Registry, 2) follow-up data are available in only 70%, and 3)
there is no information about the extent and completeness
of the available follow-up data. They report the incidence of
reoperation was 10.1% and of 2 aortic regurgitation was
14% (69).
Conclusions. From the data cited, the following general
conclusions are possible:
1) since the introduction of mechanical PHV in 1960 and
of homograft valves in 1962 to 1964, advances in PHV
have occurred in comparatively small increments except
for the introduction of bioprosthesis and of the au-
tograft;
2) the results of valve surgery with regard to survival,
complications, cardiac function, and functional class are
importantly dependent on patient-related factors and also
on type of surgery, type of prosthesis, and healthcare-
delivery related factors. Thus, one should not compare, or
at least be extremely cautious about comparing, outcomes
with use of different PHV or even the same brand of PHV
from different studies unless the baseline characteristics of
the patients is identical or at least very similar;
Table 2. Severity of VP-PM
Aortic Valve
Severity of Stenosis and VP-PM
After AVR Valve Area (cm2/m2) Clinical Status
Mild 0.9 Asymptomatic
Moderate 0.6 to 0.9 Asymptomatic (symptoms with
associated conditions)
Severe 0.6 Asymptomatic or symptomatic*
Mitral Valve
Severity of Mitral Valve Stenosis
and VP-PM After MVR Valve Area (cm2) Clinical Status
Very mild 2.0 cm2 Asymptomatic
Mild 1.5 to 2.0 Asymptomatic
Moderate 1.1 to 1.5 Usually asymptomatic, some
symptomatic
Severe 1.0 cm2 Asymptomatic or symptomatic†
*Symptoms: angina, syncope, dyspnea, heart failure, sudden death; †Symptoms associated with left atrial and pulmonary arterial
hypertension and low reduced cardiac output and their consequences.
AVR  aortic valve replacement; MVR  mitral valve replacement; VP-PM  valve prosthesis-patient mismatch.
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3) most published studies provide little or no information
about “important” patient characteristics at baseline.
There is a need for a comprehensive, but reasonable,
number of important patient characteristics at baseline
that should be provided in all PHV publications;
4) late results, especially relating to survival/mortality,
should not exclude the 30-day mortality.
5) mechanical valves:
a) there is no good evidence that any one mechanical
valve is superior with regard to patient outcomes
(among FDA-approved PHV with good documented
results at follow-up 15 years) when patient charac-
teristics at baseline are identical or are similar;
b) they have an extremely low rate of SVD;
c) the major disadvantages with use of mechanical valves
are the need for anticoagulant therapy and of bleeding
and its consequences;
d) with good anticoagulation, the risk of thromboem-
bolism with use of a mechanical PHV valve is similar
to that with use of bioprosthetic PHV without
anticoagulants; and
e) there is a subgroup of patients who are at lower risk
for thromboembolism.
6) biological valves:
a) bioprostheses:
1) there is no good evidence that any one porcine
valve is superior with regard to patient outcomes
(among FDA-approved PHV with good docu-
mented results at follow-up 15 years) when
patient characteristics at baseline are identical or
are similar;
2) SVD begins at year 5 after MVR and year 8 after
AVR;
3) SVD is greater after MVR than after AVR;
4) a minimum follow-up of15 years is necessary to
evaluate the incidence of SVD of FDA-approved
PHV;
5) the younger the patient at time of PHV implan-
tation, the higher the rate of SVD;
6) the major disadvantages with use of bioprosthesis
are the incidence of SVD and of reoperation and
their consequences including mortality;
7) if patients with biological valves need anticoagu-
lation, bleeding rates will be similar to that with
use of mechanical valves;
8) the SVD of a stentless porcine valve is similar to
that of a stented porcine valve;
9) data on patient outcomes 10 to 15 years after
PHV using stentless porcine valves are needed;
b) there is no proven benefit in patient outcomes and of
SVD with use of a homograft when compared with a
bioprosthesis; and
c) more good studies with follow-up of 15 years are
needed in adults with use of pulmonary autografts;
7) in patients age 60 to 65 years, the incidence of
bleeding without warfarin anticoagulation is not negli-
gible and can be expected to be greater with longer
follow-up. Thus, use of anticoagulants in this age group
will result in a higher bleeding rate than in younger
patients on anticoagulants. Moreover, in this age group,
SVD of bioprosthesis after AVR is very low and is low
after MVR and, thus, bioprosthesis would be the PHV
of choice in patients in these age groups; current data
shows the pericardial valve is probably superior to the
porcine valve for AVR;
8) mortality up to 10 to 15 years is high after PHV
implantation:
a) after AVR, 40% of the deaths and after MVR 40% to
60% of the deaths are related to the PHV;
b) mortality after PHV implantation is importantly
related to the age of the patient at time of insertion of
PHV and to associated cardiac and noncardiac co-
morbid conditions; and
c) subgroups of patients have a low survival at 10 years
after PHV implantation;
9) severe VP-PM is an important clinical problem after
AVR and after MVR; moderate VP-PM is a problem in
some patients after AVR and after MVR; uncomplicated
mild VP-PM is usually clinically not important; these
outcomes were predicted in the original description of
this clinical syndrome and have been shown to be
correct.
Choosing a PHV for a patient. The following factors/
issues have to be considered in choosing a PHV for an
individual patient: 1) known long-term results of PHV from
randomized trials and databases; 2) patient characteristics:
age, associated cardiovascular lesions, and comorbid condi-
tions; 3) expected survival of the patient based on age and
gender of patients, associated cardiovascular and other
comorbid conditions and known outcomes described above;
4) unique patient needs; 5) complete and accurate discussion
and information of all of the above with the patient; and 6)
joint decision by patient, cardiologist, and cardiac surgeon.
A suggested algorithm for choice of PHV for AVR for
those age 60 to 65 years and age 60 years is shown in
Figure 8. For MVR, the algorithm is the same except the
split by age is65 to 70 years and age65 years. There are
exceptions. At least three issues need to be emphasized:
1) bioprosthetic SVD after AVR is not reduced suddenly at
age 65 years or after MVR at age 70; in other words, the
major reduced rate of SVD begins a few years (5 to 10
years) earlier. Thus, if the patient is willing to accept a
“small” increased risk of SVD if PHV were to be
implanted five years earlier for the benefit of not needing
anticoagulant treatment with use of mechanical PHV,
then the decision to insert a bioprosthetic PHV at that
age may be reasonable;
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2) in certain circumstances, even though the patient needs
anticoagulant therapy for other indications such as atrial
fibrillation, it might still be preferable to insert a bio-
prosthetic valve. For example, a patient age 60 to 70
years who has atrial fibrillation is at an increased risk of
thromboemboli but is also at an increased risk of
bleeding with anticoagulant therapy. If bleeding requires
discontinuing warfarin therapy for an extended period of
time, then this puts the mechanical valve at risk of
thrombosis; therefore, one could consider insertion of a
bioprosthetic PHV; and
3) reoperating on older patients for SVD must be kept in
perspective. For example, in a patient age 65 years who
needs MVR and does not need anticoagulation for
another reason, the need of reoperating on this patient at
age 80 years for SVD may be small. The probability of
being alive 15 years after MVR may be 20%, and, if the
probability of SVD at this age is, say, 25%, then, if
initially 100 patients had MVR with a bioprosthetic
valve, only 4 of the initial 100 patients will need
reoperation.
It needs to be reemphasized that: 1) the patient is taking
the risks of complications from a choice of PHV and not the
physicians; 2) the cardiologist is the physician taking care of
the patient before PHV implantation and on follow-up; 3)
the surgeon is implanting the PHV and its replacement; 4)
therefore, the choice of PHV must be a joint decision by the
patient, cardiologist, and cardiac surgeon after a full and
complete discussion of the risks and benefits, described in
the preceding text, with the patient; and 5) both the
cardiologist and cardiac surgeon who are in the decision-
making process of choice of PHV should be very knowl-
edgeable about all the known patient outcomes with use of
various PHVs.
Reprint requests and correspondence: Dr. Shahbudin H. Ra-
himtoola, University of Southern California, 2025 Zonal Avenue,
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